| pubmed-article:21352464 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21352464 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21352464 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:21352464 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:21352464 | lifeskim:mentions | umls-concept:C0011860 | lld:lifeskim |
| pubmed-article:21352464 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:21352464 | lifeskim:mentions | umls-concept:C0441994 | lld:lifeskim |
| pubmed-article:21352464 | lifeskim:mentions | umls-concept:C0019018 | lld:lifeskim |
| pubmed-article:21352464 | lifeskim:mentions | umls-concept:C2917389 | lld:lifeskim |
| pubmed-article:21352464 | lifeskim:mentions | umls-concept:C2746078 | lld:lifeskim |
| pubmed-article:21352464 | lifeskim:mentions | umls-concept:C1442465 | lld:lifeskim |
| pubmed-article:21352464 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:21352464 | pubmed:dateCreated | 2011-4-21 | lld:pubmed |
| pubmed-article:21352464 | pubmed:abstractText | To investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of linagliptin in patients with type 2 diabetes mellitus (T2DM). | lld:pubmed |
| pubmed-article:21352464 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21352464 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21352464 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21352464 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21352464 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21352464 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21352464 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21352464 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21352464 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21352464 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21352464 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21352464 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21352464 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:21352464 | pubmed:issn | 1463-1326 | lld:pubmed |
| pubmed-article:21352464 | pubmed:author | pubmed-author:RingAA | lld:pubmed |
| pubmed-article:21352464 | pubmed:author | pubmed-author:ForstTT | lld:pubmed |
| pubmed-article:21352464 | pubmed:author | pubmed-author:DugiK AKA | lld:pubmed |
| pubmed-article:21352464 | pubmed:author | pubmed-author:RitzhauptAA | lld:pubmed |
| pubmed-article:21352464 | pubmed:author | pubmed-author:Graefe-ModyUU | lld:pubmed |
| pubmed-article:21352464 | pubmed:author | pubmed-author:Uhlig-LaskeBB | lld:pubmed |
| pubmed-article:21352464 | pubmed:copyrightInfo | © 2011 Blackwell Publishing Ltd. | lld:pubmed |
| pubmed-article:21352464 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21352464 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:21352464 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21352464 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21352464 | pubmed:pagination | 542-50 | lld:pubmed |
| pubmed-article:21352464 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:21352464 | pubmed:meshHeading | pubmed-meshheading:21352464... | lld:pubmed |
| pubmed-article:21352464 | pubmed:meshHeading | pubmed-meshheading:21352464... | lld:pubmed |
| pubmed-article:21352464 | pubmed:meshHeading | pubmed-meshheading:21352464... | lld:pubmed |
| pubmed-article:21352464 | pubmed:meshHeading | pubmed-meshheading:21352464... | lld:pubmed |
| pubmed-article:21352464 | pubmed:meshHeading | pubmed-meshheading:21352464... | lld:pubmed |
| pubmed-article:21352464 | pubmed:meshHeading | pubmed-meshheading:21352464... | lld:pubmed |
| pubmed-article:21352464 | pubmed:meshHeading | pubmed-meshheading:21352464... | lld:pubmed |
| pubmed-article:21352464 | pubmed:meshHeading | pubmed-meshheading:21352464... | lld:pubmed |
| pubmed-article:21352464 | pubmed:meshHeading | pubmed-meshheading:21352464... | lld:pubmed |
| pubmed-article:21352464 | pubmed:meshHeading | pubmed-meshheading:21352464... | lld:pubmed |
| pubmed-article:21352464 | pubmed:meshHeading | pubmed-meshheading:21352464... | lld:pubmed |
| pubmed-article:21352464 | pubmed:meshHeading | pubmed-meshheading:21352464... | lld:pubmed |
| pubmed-article:21352464 | pubmed:meshHeading | pubmed-meshheading:21352464... | lld:pubmed |
| pubmed-article:21352464 | pubmed:meshHeading | pubmed-meshheading:21352464... | lld:pubmed |
| pubmed-article:21352464 | pubmed:meshHeading | pubmed-meshheading:21352464... | lld:pubmed |
| pubmed-article:21352464 | pubmed:meshHeading | pubmed-meshheading:21352464... | lld:pubmed |
| pubmed-article:21352464 | pubmed:meshHeading | pubmed-meshheading:21352464... | lld:pubmed |
| pubmed-article:21352464 | pubmed:meshHeading | pubmed-meshheading:21352464... | lld:pubmed |
| pubmed-article:21352464 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21352464 | pubmed:articleTitle | The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. | lld:pubmed |
| pubmed-article:21352464 | pubmed:affiliation | Institut für Klinische Forschung und Entwicklung GmbH, Mainz, Germany. | lld:pubmed |
| pubmed-article:21352464 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21352464 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21352464 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21352464 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
